Artesunate repurposing for cytomegalovirus management: a systematic review of efficacy, mechanisms, and perspectives
Frontiers in Cellular and Infection Microbiology · 07.05.2026 · 16
DOI: 10.3389/fcimb.2026.1815679 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 07.05.2026. Verfasst von Haohao Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Artesunate, Antiviral Agents, Cytomegalovirus Infections, Cytomegalovirus. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) is a prevalent opportunistic pathogen associated with significant morbidity and mortality in immunocompromised individuals, particularly transplant recipients and neonates. Current antiviral therapies are often constrained by substantial toxicity and the emergence of drug resistance. Artesunate (ART), a proven antimalarial agent with established safety profiles, has been explored for potential repurposing against CMV infection, though its anti-CMV pharmacodynamics remain incompletely elucidated.
Methods
This systematic review synthesized evidence from 46 studies published through December 2025, covering in vitro , in vivo , and clinical studies, to evaluate the efficacy, mechanisms of action, and translational challenges of ART-based anti-CMV strategies.
Results
ART exhibits potent anti-CMV activity in vitro , with no reported cross-resistance to conventional antiviral agents. Structure–activity relationship analysis indicates that the endoperoxide bridge and hemisuccinate side chain may contribute to its antiviral effects. While optimized ART derivatives show improved potency, they remain in the preclinical research stage. Clinical evidence for ART is limited, primarily derived from small-scale and combination therapy studies, with inconsistent outcomes typically marked by an initial reduction in viral load rather than sustained complete clearance. Mechanistically, ART may exert anti-CMV effects through multiple host-regulated pathways, including NF-κB inhibition, G0/G1 cell cycle arrest, and modulation of mitochondrial dynamics.
Conclusions
The short plasma half-life of ART may represent a pharmacokinetic limitation to its clinical application. Further research, including formulation optimization, targeted pharmacokinetic/pharmacodynamic studies, and well-controlled clinical trials, is warranted to evaluate the potential role of ART in CMV management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Zhou, F., Song, J., Deng, C., He, X., & Ni, S. (2026). Artesunate repurposing for cytomegalovirus management: a systematic review of efficacy, mechanisms, and perspectives. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1815679
Vancouver
Zhang H, Zhou F, Song J, Deng C, He X, Ni S. Artesunate repurposing for cytomegalovirus management: a systematic review of efficacy, mechanisms, and perspectives. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1815679
BibTeX
@article{Zhang2026,
author = {Zhang, Haohao and Zhou, Fanchao and Song, Jianping and Deng, Changsheng and He, Xiao and Ni, Suiqin},
title = {Artesunate repurposing for cytomegalovirus management: a systematic review of efficacy, mechanisms, and perspectives},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1815679}
}
EUVIMED